Quarterly ResultMay 26, 2026, 04:38 PM
Inventiva Q1 2026 Cash €75.0M; Deposits €121.5M
AI Summary
Inventiva S.A. reported its financial information for the first quarter of 2026, with cash and cash equivalents at €75.0 million and short-term deposits at €121.5 million as of March 31, 2026. This represents a decrease from €99.3 million in cash and €131.6 million in deposits as of December 31, 2025, primarily due to operating activities for the lanifibranor development program. The company estimates its current financial resources will fund operations until mid-Q1 2027, with potential extension to mid-Q3 2027 if Tranche 3 warrants are fully exercised. Inventiva also reiterated the expectation for topline results of its NATiV3 trial in Q4 2026.
Key Highlights
- Inventiva's cash and cash equivalents were €75.0 million as of March 31, 2026.
- Short-term deposits amounted to €121.5 million as of March 31, 2026.
- Net cash used was primarily due to operating activities for the lanifibranor development program.
- Cash, cash equivalents, and short-term deposits are estimated to finance operations until mid-Q1 2027.
- Potential exercise of Tranche 3 warrants (up to €116.0 million) could extend financing until mid-Q3 2027.
- No revenues were recognized for the first quarter of 2026, consistent with Q1 2025.
- Topline results for the NATiV3 pivotal Phase 3 clinical trial are expected in Q4 2026.
Price Impact
More from IVA